Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data
ConditionHepatitis C Virus (HCV)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAbbVie
About this trial
The objective of this study is to assess the safety, tolerability and effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) in participants taking either prescribed or illicit drugs.
Eligibility criteria
Qualifiers
Prescribed 8 weeks of Glecaprevir/Pibrentasvir (G/P).
Treatment-naïve (for the current infection, participants that may have had prior infections which were resolved with treatment are considered naive for current infection as long as they have not received any treatment for the current infection.)
Is concomitantly on one or more prescription medications or illicit drugs.
Disqualifiers
Treated with DAAs other than G/P.
History of decompensated cirrhosis.
Had Hepatitis-B virus (HBV) infection.
Had hepatocellular carcinoma (HCC).
Trial design
Treatments tested in this trial
- Not listed
Trial groups
2,000 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov